Table 1.

Characteristics of all evaluable patients (N = 21)

Characteristics	Median (range)	Number (%)
Age, y	52 (30–67)
Sex  Female  Male		15 (71) 6 (29)
KPS	70 (60–90)
Histology  Non-small-cell lung cancer   ALK+   EGFR+   ROS1+  Breast carcinoma   ER + HER2−   ER + HER2+   ER-HER2+   TN  Esophageal adenocarcinoma  Rectal adenocarcinoma  Adenoid cystic carcinoma  of parotid		11 (52) 1 (5) 7 (33) 1 (5) 7 (33) 3 (14) 1 (5) 1 (5) 2 (10) 1 (5) 1 (5) 1 (5)
LM Diagnosis at Enrollment Newly diagnosed LM LM progression on prior therapies		9 (43) 12 (57)
Number of Prior Metastatic Disease Therapies at Enrollment  Systemic Therapies   Afatinib   Alectinib   Brigatinib   Enctrectinib   Erlotinib   Lorlatinib   Osimertinib  Local Therapies (surgery, radiation  therapy)		2 (0*-5) 1 (5) 1 (5) 1 (5) 1 (5) 4 (19) 1 (5) 7 (33) 1 (0-6)
Baseline Evaluation  Positive MRI  Positive cytology		21 (100) 16 (76)
With Parenchymal Brain Metastases at Enrollment  Yes  No		11 (52) 10 (48)

Abbreviations: EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; KPS = Karnofsky performance status; LM = leptomeningeal metastasis; MRI = magnetic resonance imaging; ROS1 = ROS proto-oncogene 1; TN = triple negative breast cancer

*One patient with metastatic adenoid cystic carcinoma of parotid did not receive prior systemic therapy prior to enrollment